Physician profile
William D Bugbee
NPI 1780642884
$2,065,419.47
in general payments reported to CMS, 2019-2025
20 companies · $371K in 2025
The $371K reported for 2025 was more than what 96% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $63K · 2021: $608K · 2022: $315K · 2023: $343K · 2024: $298K · 2025: $371K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $694K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $157K · Consulting Fee: $150K · Travel and Lodging: $8,576 · Food and Beverage: $1,932 · Honoraria: $1,103 · Entertainment: $18.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $693,840.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,795.00 |
| Consulting Fee | $149,700.60 |
| Travel and Lodging | $8,576.40 |
| Food and Beverage | $1,931.74 |
| Honoraria | $1,102.50 |
| Entertainment | $18.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $618,697.95 | 2019-2025 | Djo Surgical |
| Orthalign INC | $432,318.02 | 2019-2025 | Orthalign Plus |
| Joint Restoration Foundation, INC. | $357,489.78 | 2019-2025 | |
| Smith+Nephew, INC. | $286,624.85 | 2019-2025 | Journey II, Real Intelligence |
| Depuy Synthes Products, INC. | $245,949.94 | 2019-2022 | |
| Medical Device Business Services, INC. | $49,270.51 | 2019-2023 | Pinnacle, Attune, Actis |
| Arthrex, INC. | $43,279.55 | 2019-2024 | Arthrex |
| Moximed, INC | $16,200.00 | 2025 | Misha Knee System, Small, Left |
| Bioventus LLC | $9,973.40 | 2021-2023 | |
| Insight Medical Systems, INC. | $2,674.00 | 2019-2021 | |
| Davol INC. | $1,120.70 | 2025 | Arista |
| Zimmer Biomet Holdings, INC. | $603.11 | 2020-2025 | Mymobility Platform, Persona |
| Aesculap Biologics, LLC | $438.99 | 2019-2022 | |
| Overture Orthopaedics | $278.53 | 2025 | Overtureti |
| Stryker Corporation | $227.88 | 2021-2024 | Mako |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $105.14 | 2023 | Maci |
| Depuy Synthes Sales INC. | $66.75 | 2020-2024 | Orthovisc |
| Solventum Corporation | $47.95 | 2025 | Prevena |
| Spinesmith Holdings, LLC | $26.77 | 2019 | |
| Ferring Pharmaceuticals INC. | $25.65 | 2025 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$512,747.24 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bugbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.